Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013003729 - COMPOSITIONS, METHODS AND KITS FOR TREATING LEUKEMIA

Publication Number WO/2013/003729
Publication Date 03.01.2013
International Application No. PCT/US2012/044946
International Filing Date 29.06.2012
IPC
A01N 37/08 2006.01
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
37Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
08containing carboxylic groups or thio-analogues thereof, directly attached by the carbon atom to a cycloaliphatic ring; Derivatives thereof
CPC
A61K 31/202
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
202having three or more double bonds, e.g. linolenic
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/5575
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
557Eicosanoids, e.g. leukotrienes ; or prostaglandins
5575having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
02specific for leukemia
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • THE PENN STATE RESEARCH FOUNDATION [US]/[US] (AllExceptUS)
  • PRABHU, Kumble, Sandeep [US]/[US] (UsOnly)
  • PAULSON, Robert, Frank [US]/[US] (UsOnly)
  • HEGDE, Shailaja [IN]/[US] (UsOnly)
  • KAUSHAL, Naveen [IN]/[US] (UsOnly)
  • GANDHI, Ujjawal, Hitendra [IN]/[US] (UsOnly)
Inventors
  • PRABHU, Kumble, Sandeep
  • PAULSON, Robert, Frank
  • HEGDE, Shailaja
  • KAUSHAL, Naveen
  • GANDHI, Ujjawal, Hitendra
Agents
  • DOBBELAERE, Amy, A.
Priority Data
61/502,67729.06.2011US
61/535,14915.09.2011US
61/635,45819.04.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS, METHODS AND KITS FOR TREATING LEUKEMIA
(FR) COMPOSITIONS, MÉTHODES ET NÉCESSAIRES POUR TRAITER LA LEUCÉMIE
Abstract
(EN)
Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin J3 or a derivative thereof, or a prostaglandin D receptor (DP) agonist. The compositions may further include a second anti-cancer drug. Δ12-prostaglandin J3 is a stable metabolite of omega-3 fatty acid, eicosapentaenoic acid (EPA), and was discovered to have anti-leukemic properties. The compositions, kits and methods may be particularly useful for treating human subjects who are resistant to one or more anti-cancer drugs.
(FR)
L'invention concerne des compositions, des nécessaires et des méthodes qui permettent de traiter la leucémie chez un sujet (par exemple un être humain) et qui comprennent un premier médicament anticancéreux qui est constitué par Δ12-prostaglandine J3 ou un dérivé de celle-ci, ou un agoniste du récepteur de prostaglandine D (DP). Les compositions peuvent en outre comprendre un second médicament anticancéreux. Δ12-prostaglandine J3 est un métabolite stable de l'acide gras oméga 3, de l'acide eicosapentaénoïque (EPA) et s'est avéré posséder des propriétés anti-leucémiques. Les compositions, les nécessaires et les méthodes peuvent être particulièrement utiles pour le traitement de sujets humains qui sont résistants à un ou à plusieurs médicaments anticancéreux.
Latest bibliographic data on file with the International Bureau